Pioneering gene therapy takes aim at inherited blindness

June 29, 2015, University of Alberta Faculty of Medicine & Dentistry
A clinical research trial injects a customized virus to transfer a healthy gene into a retina. Credit: Alberta Health Services

Canada's first human gene therapy trial for eyes—the replacement of a faulty gene with a healthy one—is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people with a genetic disorder that leaves them blind by middle age.

"It's a great privilege to be able to do something very positive for people with choroideremia," says clinical research team leader Dr. Ian MacDonald, an with Alberta Health Services and professor with the Faculty of Medicine & Dentistry at the University of Alberta, sponsor of the research. "People have hoped for this for a long time."

Choroideremia is a form of inherited blindness that affects one in 50,000 people, about 90 per cent of whom are men. Many experience difficulty seeing at night during their teens, lose peripheral vision in adulthood and are often legally blind by the age of 40. The disease is caused by a that results in the degeneration of the light-sensing retinal cells at the back of the eye. Until now, it has been untreatable.

Gene therapy is not a drug but rather a transfer of human genes. Gene therapy refers to the incorporation of new DNA into cells, either to replace a gene that is missing or not functioning. This allows the cells to produce an important protein. In choroideremia, this protein is not produced and retinal cells die off over time, causing vision to deteriorate.

Dr. MacDonald's trial involves a new treatment intended to stop choroideremia in its tracks with a single injection of what's known as a viral vector—a small harmless virus that's been modified to carry into the eye the 'good' gene needed to potentially prevent further loss of sight and to restore the vision of his patients—often with noticeable results in under a month.

During the procedure, performed under a general anesthetic, a surgeon detaches the area to be injected in the patient's retina, then injects the viral vector through a narrow needle into the back of the eye. The injection carries about 10 billion viral particles, each carrying a working copy of the good CHM gene, to target millions of eye cells.

"We're using the natural properties of a virus, its ability to inject its DNA into human cells, to introduce a working copy of the needed gene into the retinal layers," says Stephanie Chan, genetic counsellor and study co-ordinator. "The idea is that those cells will take up the good gene and use it to create the correct protein, replacing the defective gene that's in the cells."

The first of six local men to undergo ocular , Ken Ross had about five per cent vision remaining in his right eye. Following treatment, the 43-year-old Edmonton man already sees improvement in his ability to tell colours apart and distinguish light and shadow.

"I'm still trying to wrap my head around it," Ross says with emotion.

"I didn't foresee this happening in my lifetime. I'll try not to cry. I've been seeing Dr. MacDonald since I was little. I got tested, hoping to take part in the trial, last August. Then my spouse and I went on a cruise. I was sitting on a ship's balcony thinking, 'This is just my lot in life. I'll enjoy the view while I can and keep the memory inside.' And when I came back, I got the call that I qualified for the surgery."

The viral vector, known as AAV2-REP1, was provided by NightstaRx Ltd., a private British biopharmaceutical company focused on the development of therapies for retinal dystrophies.

"We are leading the way in the development of an effective gene therapy treatment for choroideremia and this new study, sponsored by the University of Alberta, is another step forward in the development of AAV2-REP1," says David Fellows, CEO of NightstaRx. "We have been granted Orphan Drug Designation for the product in the United States and Europe and the data to date has shown very promising results."

The first clinical trials took place at the University of Oxford. Results published in The Lancet Medical Journal in 2014 reported that six months after treatment, the first six patients showed improvement in their vision in dim light; and two of the six were able to read more lines on an eye chart. Oxford research is ongoing under the direction of ophthalmologist Dr. Robert MacLaren.

Funds, support and equipment for the Canadian trial have been provided by various governmental and private agencies, including Alberta Innovates - Health Solutions (AIHS); Canadian Institutes of Health Research (CIHR); NightstaRx; Canada Foundation for Innovation; Alberta Innovates (Alberta Innovation and Advanced Education); The Foundation Fighting Blindness (FFB); Choroideremia Research Foundation Canada (CRFC); and private donors.

Researchers believe this new approach to eye therapy has promise for treating people early on before too many cells in the retina have been lost. It may also have relevance for other, far more common causes of blindness, such as retinitis pigmentosa and age-related macular degeneration.

"If we can maintain the vision our patients have, we would look at that as a success," says Chan. "If there is improvement, that's even better."

Dr. MacDonald says he's "absolutely impressed" by the eye's ability to heal itself and reattach the retina within hours of surgery. "The human body is doing its work. We're just helping it."

Explore further: Gene therapy improves eyesight in people born with an incurable form of blindness

Related Stories

Gene therapy improves eyesight in people born with an incurable form of blindness

January 15, 2014
A new gene therapy has restored some sight in people born with an inherited, progressive form of blindness. The technique replaces a defective gene in the eye with a normal working copy of the gene using a single injection.

Ohio State researchers design a viral vector to treat a genetic form of blindness

November 2, 2011
Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness ...

Finding hope in the dark

June 10, 2015
Advances in stem cell transplantation and gene therapy have been pioneered in vision research. An international team of researchers from Bristol, Toronto, Pittsburgh, Dallas and Montreal have identified a gene that could ...

Study points way forward for retinal disease gene therapy

May 3, 2015
Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes vision loss starting in childhood, improved patients' eyesight and the sensitivity of the retina within weeks of treatment. Both of these ...

Team develops novel gene therapy for achromatopsia

May 8, 2015
Researchers from the University of Pennsylvania and Michigan State University presented new preclinical data this week that evaluates the efficacy of a gene therapy treatment for achromatopsia, a rare inherited retinal disease ...

First patient receives novel gene therapy for type of blindness

October 28, 2011
(Medical Xpress) -- The first patient to receive gene therapy for an incurable type of blindness was treated at the John Radcliffe Hospital in Oxford this week as part of a trial led by Oxford University.

Recommended for you

Satellite imaging techniques may help reduce preventable vision loss

May 11, 2018
By adapting pattern recognition techniques used to assess satellite images, scientists have devised a novel way to diagnose blinding eye diseases, such as age-related macular degeneration.

Ophthalmologists link immunotherapy with a serious eye condition

May 7, 2018
New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

Burnout, depression can affect ophthalmology residents, study finds

May 4, 2018
A new study led by Brown University researchers finds that ophthalmology residents across the U.S. face a substantial burden of burnout and depression, which may affect not only the residents themselves but also the quality ...

AI better than most human experts at detecting cause of preemie blindness

May 3, 2018
An algorithm that uses artificial intelligence can automatically and more accurately diagnose a potentially devastating cause of childhood blindness than most expert physicians, a paper published in JAMA Ophthalmology suggests.

New diagnostic technique picks up the S in vision

May 1, 2018
A new technique that could help improve diagnosis of vision disorders has been successfully tested at the University of Bradford, UK.

A bit of dark chocolate might sweeten your vision

April 26, 2018
It may not replace prescription glasses, but a few bites of dark chocolate might offer a slight and temporary bump up in vision quality, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.